Our four best-in-class, cGMP-compliant formulation manufacturing facilities manufacture a wide range of injectables using aseptic filling or terminal sterilization, as applicable. The facilities are equipped for production flexibility and can switch product lines seamlessly, eliminating need to install additional production lines to meet altered product specifications and market mechanics of demand and supply.
Our facilities have been inspected by the following regulatory bodies and received several product approvals:
Our 600,000 sq. ft. flagship sterile injectable facility in Dundigal, Hyderabad has been manufacturing products to the USA since 2004, possesses capabilities across various delivery formats.
Our 584,459 sq. ft. state of the art sterile facility at Pashamylaram, Hyderabad, commissioned in July 2012, started manufacturing products to the US market from September 2016. Output at this facility has nearly doubled our manufacturing capacity.
A dedicated Penems facility, after filing its first ANDA in September 2013, started manufacturing products to the US market from April 2016.
Our oncology facility, commissioned in the year 2010 started manufacturing products to the US in 2016 and to EU in 2015.
Our 4 API manufacturing facilities have in-house manufacturing capabilities that help us integrate backwards and develop products that many others may overlook because of API supply uncertainty.
Know More
Our two state-of-the-art R&D divisions in Hyderabad are staffed by nearly 300 qualified scientists. The labs engage in Formulation Development, Analytical Method Development, API Process Development and Stability Studies.
Know More
